Phase 4 N=180 ZOSTAVAX™ Safety and Immunogenicity in Korean Adults (V211-034)
Herpes Zoster · Shingles
Primary: Geometric Mean Fold Rise (GMFR) From Day 1 in Varicella Zoster Virus (VZV) Antibody — 2.8 Ratio
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=40 Lubiprostone and Mucus Secretion in Patients With Chronic Constipation
Constipation
Primary: Change of Mucus and Mucin Secretion in Patients With Chronic Constipation and in Controls. — 260; 133; 229; 161 mg/hour
Phase 2 N=291 Broccoli Sprout Intervention in Qidong, P.R. China
Environmental Carcinogenesis
Primary: Effect of Treatment on Levels of Air Toxics Mercapturic Acids Over Intervention Period — 1.700; 1.065 pmol/mg creatinine
N/A N=9 Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies
Breast Cancer
Primary: Safety — 9 participants
Phase 3 N=764 A Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Japanese Elderly Adults Aged 65 Years Old and Older
Pneumococcal Vaccines · Pneumococcal Conjugate Vaccine
Primary: Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for 12 Common Serotypes 1 Month After Vaccination — 103; 78; 44; 61 titer
N/A N=102 Retardation of Myopia in Orthokeratology
Myopia
Primary: Axial Elongation in the Study and Control Subjects Who Completed the Two Years Study — 0.36; 0.63 mm
Phase 4 N=114 Study to Measure the Safety of Paliperidone ER (Extended-release) in Patients With Liver Disease
Schizophrenia · Schizoaffective Disorder · Psychotic Disorders
Primary: The Difference in the Incidence of Any Adverse Events When Patients Switch Their Antipsychotic From Treatment as Usual (TAU) to Paliperidone ER — 0; 2; 27; 43 Participants
N/A N=933 Observational Study of Lumigan® 0.01% for Treatment of Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
Open-Angle Glaucoma · Ocular Hypertension
Primary: Intraocular Pressure (IOP) at Baseline — 22.04; 22.07 mm Hg
Phase 2 N=44 Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma
Neuroblastoma · Sarcoma · Rhabdomyosarcoma-Embryonal
Primary: Number of Participants With a Positive Immune Response as Evidenced by the Delayed Type of Hypersensitivity (DTH) Reaction Assay — 0; 15 Participants — p=0.043
N/A N=40 Sutureless Cryopreserved Amniotic Membrane Graft (ProKera) and Wound Healing After Photorefractive Keratectomy
Corneal Wound Healing
Primary: Number of Days to Complete Re-epithelialization — 4.6; 4.1 days to complete re-epithelialization
Phase 3 N=344 Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Infections, Papillomavirus
Primary: Number of Subjects With Any, Grade 3 and Related Serious Adverse Events (SAEs) — 8; 5; 0 Subjects
N/A N=40 Lung Collapse With Bronchial Blocker
Video-assisted Thoracoscopic Surgery · Lung Isolation Device · One-lung Ventilation
Primary: Time to Obtain Complete Lung Collapse — 47.8; 32.5 minutes
Phase 3 N=48 A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)
Alzheimer's Disease · Mild Cognitive Impairment
Primary: Qualitative Amyloid Image Assessment — 12; 5; 3; 3 participants — p=0.0253
Phase 3 N=69 Radiation Therapy Cisplatin With or Without Fluorouracil Patients With Stage III or Stage IV Head and Neck Cancer
Head and Neck Cancer
Primary: Relapse Free Survival — 30; 28 participants
Phase 1 N=7 A Study of Florbetapir (18F) in Japanese Healthy Volunteers
Alzheimer's Disease
Primary: Whole Body Radiation Dosimetry — 0.0186; 0.0132; 0.0179; 0.0157 mSv/MBq